Ann Clin Case Rep | Volume 7, Issue 1 | Case Report | Open Access
D’Addario C1*#, Sergi MC1#, Biasi A1, Scardapane A2, Gatti P3 and Stucci LS1
1Department of Interdisciplinary Medicine, University of Bari, “Aldo Moro”, Italy
2Department of Interdisciplinary Medicine, Section of Diagnostic Imaging, University of Bari, “Aldo Moro”, Italy
3Department of Internal Medicine, Perrino Hospital, Brindisi, Italy
#These authors contributed equally to this work
*Correspondance to: Claudia D’AddarioFulltext PDF
Breast cancer accounts for 43% of all solid tumors in women. Despite continuous improvement in therapy, breast cancer represents the main cause of cancer death in women. Notwithstanding the notable increase in the early diagnoses made possible by the spread of screening tests, still, 5% of breast malignancies show up as metastatic ‘de novo’. We report the case of a 56-years-old woman who, under a first-line therapy with Ribociclib and Fulvestrant developed pseudocirrhosis of the liver, i.e., liver cirrhosis due to the malignancy, but unrelated to the presence of liver metastases. This condition is a rare and poorly known clinical entity. There is no consensus on the criteria needed for diagnosis. Pathogenic mechanisms underlying etiology may be chemotherapy’s toxicity or architectural changes in response to neoplastic micro-infiltration. However, an increase in transaminases and liver dysfunction are described with CDK 4/6 inhibitors therapy, probably due to direct drug-induced hepatotoxicity, immune-mediated activity, and production of toxic metabolites. Early hepatic alterations and/or radiological evidence of liver cirrhosis in the absence of neoplastic liver involvement, should suggest the diagnosis of such a rare condition.
D’Addario C, Sergi MC, Biasi A, Scardapane A, Gatti P, Stucci LS. Pseudo-Cirrhosis of the Liver from Breast Cancer: A Case Report. Ann Clin Case Rep. 2022; 7: 2359.